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Bordetella pertussis (Bp) is the causative agent of pertussis, a vaccine preventable disease occurring primarily in children. In recent
years, there has been increased reporting of pertussis. Current pertussis vaccines are acellular and consist of Bp proteins including
the major virulence factor pertussis toxin (Ptx), a 5-subunit exotoxin. Variation in Ptx subunit amino acid (AA) sequence could
possibly aﬀect the immune response. A blind comparative mass spectrometric (MS) analysis of commercially available Ptx as
well as the chemically modiﬁed toxoid (Ptxd) from licensed vaccines was performed to assess peptide sequence and AA coverage
variability as well as relative amounts of Ptx subunits. Qualitatively, there are similarities among the various sources based on AA
percent coverages and MS/MS fragmentation proﬁles. Additionally, based on a label-free mass spectrometry-based quantiﬁcation
method there is diﬀerential relative abundance of the subunits among the sources.
1.Introduction
Bordetella pertussis (Bp), a gram-negative bacterium, is the
causative agent of pertussis, commonly known as whooping
cough [1]. Pertussis is a highly communicable respiratory
infection that in the absence of vaccination primarily aﬄicts
infants and children. Transmission occurs via direct contact
with discharges from respiratory mucous membranes of
infected persons. Persons who contract pertussis develop
a persistent cough that includes the characteristic high-
pitched “whoop” sound that can last up to eight weeks
[1,2].Pertussisisavaccinepreventablediseasebutaccording
to the World Health Organization (WHO), there are an
estimated 50 million cases of pertussis per year worldwide
with approximately 300,000 leading to death [3, 4]. The
majority of the high mortality rates come from developing
countries. In the United States acellular pertussis vaccines
are administered to infants and young children [5]a n d
in 2006 were recommended for adolescents and adults [6–
8]. Acellular vaccines consist of up to ﬁve Bp components
including the major virulence factor pertussis toxin (Ptx),
ﬁlamentous hemagluttinin, pertactin, ﬁmbrae 2, and/or
ﬁmbrae 3 [3]. Pertussis vaccines are generally formulated in
combination with vaccine immunogens for other diseases,
such as tetanus and diphtheria [9].
Ptx, a ﬁve-subunit protein complex (S1–S5) is a major
bacterial exotoxin, surface adhesin, and porin, is involved
in the establishment of infection in humans and has been
shown to be an important component of the vaccine
[10]. Ptx, a ∼105kDa A-B protein complex, comprises
the protomer (A) and oligomer (B). The A component
consists of S1 (∼22kDa), which contains ADP ribosylation
enzymatic activity and is the most immunoreactive region
of the toxin. The B portion consists of S2, S3, S4, and S5,
decreasing in size from ∼20kDa to 10kDa, respectively, and
is associated with adherence to human host cells [11, 12].2 Journal of Biomedicine and Biotechnology
From a cellular perspective, the B portion binds to cells
inducing the enzymatic activity of S1 and its transversion
into the cell, followed by inactivation of G proteins by S1 and
subsequent initiation of an intracellular cascade of signaling
events which includes factors that regulate the immune
response [11]. Importantly, the Ptxs in current vaccines have
been inactivated (toxoids; Ptxd) by covalent crosslinkages
formed using agents such as formaldehyde or glutaraldehyde
[13, 14].
Recently, the U.S. and several other countries have
reported an increase in pertussis cases. Factors such as
waning immunity after natural infection or immunization,
improved molecular-based diagnostics, increased surveil-
lance, or changes in circulating strain antigenicity have all
been hypothesized as contributing factors [3]a n dh a v e
led researchers to re-examine pertussis vaccine components
and preparation strategies. Changes in Ptx subunit protein
sequences as well as the amounts present in the vaccine
formulationcouldaﬀecttheoverallimmuneresponse.More-
over, identiﬁcation of commonalities as well as potential
disparities of various Ptx and Ptxd sources on a proteomic
level could provide insight into changes in population
immune responses to the vaccine.
Mass spectrometry (MS), a powerful and sensitive
analytical tool has been used to identify, diﬀerentiate,
and characterize proteins in complex mixtures [15]. In
particular, MS techniques, such as liquid chromatography-
electrospray ionization (LC-ESI) tandem MS (MS/MS) or
matrix-assisted laser desorption ionization time-of-ﬂight
(MALDI-TOF) MS/MS, which vary in their rapidity and
sensitivity of peptide detection as a result of enzymatic
cleavage, are commonly used in proteomic analysis [15, 16].
Proteins can be proteolytically cleaved by enzymes such as
trypsin and the peptides generated are ionized and separated
based on their mass-to-charge ratios. The peptides and the
proteins, from which they originated, are identiﬁed based
on comparisons between the MS/MS fragmentation patterns
and protein databases. [17]. For instance, Bottero et al. used
MALDI-TOF MS/MS as a means to characterize enriched
Bp membrane proteins, which included the Ptx S1, from
diﬀerent strains [18]. Alternatively, Tumala and colleagues
have used liquid chromatography MS/MS (LC-MS/MS) to
accurately measure the molecular weights of Ptx subunits as
well as to identify novel chemical modiﬁcation sites [19].
In this study, a blind comparative mass spectrometric
analysis of Ptx and Ptxd from multiple sources was per-
formed to assess potential sequence and amino acid (AA)
coverage variability as well as relative amounts of pertussis
toxin subunits. This ﬁrst-phase study demonstrates the
sensitivityofmassspectrometryinascertainingdiﬀerencesat
the peptide sequence level and may provide a basis for future
correlative immunoproteomic studies.
2. Methods
2.1. Pertussis Toxin and Toxoid Sources. The commercially
available Ptx and Ptxd were purchased from Protein
Express, Inc. (Cincinnati, OH, USA), LIST Biologicals, Inc.
(Campbell, CA, USA), Sanoﬁ Pasteur Pharmaceutical (Paris,
France), or GSK Pharmaceutical (London, UK). The sources
were blindly assigned a letter, in which Ptxs are represented
as A or B, while the chemically inactivated Ptxd samples are
denoted as C or D.
2.2. Pertussis Toxin and Toxoid Digestions. The Ptx and Ptxd
sources (10μg) were vortexed and precipitated with 100%
acetonitrile (ACN), for 60 minutes, and then dried using a
vacuum centrifuge. Trypsin (5μg) (Promega Corporation,
Madison, WI, USA) was added and the volume was brought
to 100μL with tryptic digestion buﬀer (50mM ammonium
bicarbonate adjusted to pH 8.5 with NaOH, 0.6mM CaCl2,
0.1% (w/v) potassium azide (KN3), and 3mg/L phenol
red). The samples were incubated at 37
◦C for 3, 6, and 24
hours. Digested samples (250ng total) were subsequently
prepared for either MALDI-TOF MS/MS or LC-MS/MS.
Additionally, in separate experiments, samples were treated
with an acid cleavable detergent, RapiGest (RG; Waters
Corporation, Milford, MA, USA) to assess the eﬃciency of
tryptic digestion. 0.1% RG in tryptic digestion buﬀer was
added to Ptx or Ptxd (10μg) samples. The samples were next
incubated at 100
◦C for 5 minutes followed by cooling at
room temperature with the subsequent addition of trypsin
(5μg). Trypsin digestions were performed as stated above.
However, prior to MS analysis, the RG was inactivated by
cleavage with 0.175M HCL at 37
◦C for 30 minutes, and the
supernatant (obtained by centrifugation for 15 minutes at
17,300g) was transferred to a new vial.
2.3. MS Sample Preparation. Samples for MALDI-TOF
M S / M Sw e r er e s u s p e n d e di na ne q u a lv o l u m eo f0 . 1 %
triﬂuoroacetic acid (TFA), and the peptides were separated
using a C18 zip-tip minicolumn (Millipore Corporation,
Billerica, MA, USA) and eluted in two steps with 3μLo f
3 0 %A C Ni n0 . 1 %T F Aa n dt h e n3 μL of 80% ACN in
0.1% TFA. The eluates were mixed with 10μL α-cyano-4-
hydroxycinnamic acid (α-CHCA) (Sigma Aldrich, St. Louis,
MO, USA) and 0.5μL was next spotted on to a stainless steel
plate. A protein mix diluted at 1:10 was spotted on the plate
in the appropriate wells and used for instrument calibration
purposes. For LC-MS/MS, samples were simply resuspended
in equal volumes of 0.1% formic acid (FA).
2.4. Mass Spectrometry
2.4.1. MALDI-TOF MS/MS. Mass spectra of each sample
well were obtained by scanning from 800 to 4000m/z in
MS positive-ion reﬂector mode on the Applied Biosystems
4800 Proteomics Analyzer (Framingham, MA, USA). The
instrument uses a nd:YAG laser at 337nm with a 200MHz
repetition rate, and each spectrum is an average of 1000
laser shots. In MS/MS mode, the CID spectra were generated
using air as the collision gas at 1kV and an average of
500 laser shots for MS/MS acquisition. The instrument
was tuned and calibrated for MS analysis using a mix-
ture of ﬁve peptides: des-Arg1-Bradykinin (m/z 904.47),
angiotensin I (m/z 1,296.69), Glu1-ﬁbrinopeptide B (m/z
1,570.68), ACTH (1–17)(m/z 2093.08), and ACTH (18–
39)(m/z 2,465.20). For MS/MS mass calibration, knownJournal of Biomedicine and Biotechnology 3
fragment ion masses observed in the Glu1-ﬁbrinopeptide B
were used. The instrument was programmed for automated
MS/MS acquisition using data dependent acquisition (DDA)
mode.SelectedpeptidesweresubjectedtoMS/MSanalysisto
conﬁrm their identity through sequence determination.
All MS/MS spectra were automatically submitted to a
Mascot Server through Mascot Distiller (Matrix Science Inc.,
London, UK; version 2.2.1.0) and searched against the entire
NCBInr database or a modiﬁed NCBInr database created to
search“Bordetella” or “pertussis”proteins with deamidation,
oxidation and carbamidomethylation assigned as variable
modiﬁcations. Tryptic constraints were applied, allowing up
to two missed cleavages. Peptide searches were performed
with an initial tolerance on mass measurement of 100ppm
in MS mode and 150ppm in MS/MS mode. All matched
peptides were veriﬁed manually and the searches combined
andpr ocessedb yScaﬀold(ProteomeSoftwareInc.,Portland,
OR, USA; version 2.03.01).
2.4.2. Nano-LC ESI-MS/MS (LTQ-Orbitrap). Protein iden-
tiﬁcation was achieved by using nanoﬂow liquid chro-
matography, data-dependant tandem mass spectrometry,
and database searching. A 365μmb y7 5 μm fused silica
pulled needle capillary (New Objective, Inc., Woburn, MA)
was ﬁlled in house with 10cm of 5μm Symmetry 300 reverse
phase packing material (Waters Inc., Bedford, MA). Protein
digests were directly loaded onto the analytical column with-
out using a trap column and introduced using an Eksigent
autosampler. The gradient was delivered by an Eksigent 2D
nanoLC system (Eksigent Technologies, Inc, Dublin, CA)
where the mobile phase solvents consisted of: (solvent A)
0.2% formic acid (Thermo Scientiﬁc, Rockford, IL), 0.005%
triﬂuoroacetic acid (Sigma-Aldrich) in water (Burdick and
Jackson, Muskegon, MI), (solvent B) 0.2% formic acid,
and 0.005% triﬂuoroacetic acid in acetonitrile (Burdick and
Jackson). The gradient ﬂow was set at 400nL/min, and the
proﬁleconsistedofaholdat5%Bfor5minutesfollowedbya
ramp to 30% B over 100 minutes then a ramp up to 90% B in
5 minutes and a hold at 90% for 2 minutes before returning
to 5% B in 2 minutes and re-equilibration at 5% B for
20 minutes. Peptides were nano-electrosprayed into an LTQ
Orbitrap tandem mass spectrometer (Thermo Scientiﬁc, San
Jose, CA). The voltage applied to the nano-electrospray
source was 2.0kV. The mass spectrometer was programmed
to perform data-dependant acquisition by scanning the mass
range from m/z 400 to 1600 at a nominal resolution setting
of 60,000 for parent ion acquisition in the Orbitrap. Then
tandem mass spectra of doubly-charged and higher-charge
states were acquired for the top 10 most intense ions. Singly-
charged ions were not considered for MS/MS. All tandem
mass spectra were recorded using the linear ion trap. This
DDA process cycled continuously throughout the duration
of the gradient.
All tandem mass spectra were extracted from the raw
dataﬁleusingMascotDistiller(MatrixScience,London,UK;
version 2.2.1.0) and searched using Mascot (version 2.2.0).
Mascot was setup to search using the entire NCBInr database
oramodiﬁedNCBInrdatabasecreatedtosearch“Bordetella”
or “pertussis” recognized proteins in which trypsin is used
as the digestion agent. Mascot was searched with a fragment
ion tolerance mass of 0.80Da and a parent ion tolerance
of 200ppm. Variable modiﬁcations for the mascot search
were deamidation, oxidation, and carbamidomethylation.
Scaﬀold was used to validate MS/MS-based peptide and
protein identiﬁcations. Peptide identiﬁcations were accepted
if they could be established at greater than 95.0% probability
as speciﬁed by the Peptide Prophet algorithm [20]. Protein
identiﬁcations were accepted if they could be established
at greater than 99.0% probability and contained at least 2
identiﬁed peptides [21]. With these stringent parameters of
Peptide Prophet and Protein Prophet, the false discovery rate
was zero.
2.4.3. Nano-LC ESI-MS/MS (Q-Tof Premier). LC-MS/MS
was carried out using a nanoAcquity ultra-performance liq-
uid chromatography (UPLC) coupled to a QTof Premier MS
system (Waters Corporation). LC separation was performed
using a Symmetry C18 trapping column and a BEH C18
column (100μmI . D .× 100mm long with 1.7μm packing),
at a ﬂow rate of 1.2μL/min. Standard water/ACN gradients
containing 0.1% formic acid in both solvents were used for
elution, with the ACN increasing linearly from 1% to 50%
in 50 minutes, and an overall cycle time of 90 minutes.
The QTof utilized an MSE (or Protein Expression) method,
which involved acquiring data-independent alternating low-
and high-energy scans over the m/z range 50–1990 in 0.6
second, along with lockmass data on a separate channel to
obtain accurate mass measurement. The data obtained using
the MSE method were further processed using ProteinLynx
Global Server v2.3, which provided statistically validated
peptide and protein identiﬁcation using a SwissProt-Trembl
protein database, along with relative protein quantiﬁcation
analysis. Root mean square mass accuracies were typically
within 8ppm for the MS data, and within 15ppm for
MS/MS data. Also the false positive rate was 4%. Lastly,
the relative quantiﬁcation assessed in this study used an
internal standard from a known protein and is considered
as u r r o g a t e .
3. Results
A mass spectrometric analysis was performed to assess pro-
tein sequence homogeneity of Ptx and Ptxd. MALDI-TOF
MS/MS, and LC-MS/MS approaches revealed comparable to
varying AA percent composition proﬁles (percent is based
on the number of AA (within tryptic peptides) generated
divided by the total number of AA in the protein) among
Ptx and Ptxd (Table 1) as well as a compilation of detected
peptides (Table 2). Generally, Ptx A and B digested with
trypsingeneratedhigherAAcoveragesamongthenontreated
oligomeric subunits compared to their chemically modiﬁed
Ptxd counterparts regardless of the MS system used. Addi-
tionally,trypsindigestsofPtxBgeneratedthehighestaverage
among S2–S5 compared to all samples. Also, for both Ptxd
samples there was low to no detection of S2–S5 peptides.
However, AA coverage reports for S1 on average
between Ptx and Ptxd were fairly comparable with 45 and
44%, respectively. Probing further, LC-MS/MS instruments4 Journal of Biomedicine and Biotechnology
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Figure 1: MS/MS spectra illustrating similar fragmentation proﬁles of Subunit 1 peptide GTGHFIGIYEVR from representative pertussis
toxin (B) and pertussis toxoid (C). Nano Liquid Chromatography MS/MS were performed using the LTQ-Orbitrap on tryptic peptides
obtained from pertussis toxin B and pertussis toxoid C. The MS/MS data was searched against the NCBI database and the peptide spectrum
was analyzed [comparing relative peak intensity (0–100%) versus mass/charge (0 to 1500)] using the Scaﬀold software. The red and blue
lines represent y- and b-ion distribution peaks, respectively.
Table 1:Comparativetoxinandtoxoidsequenceanalysis(%amino
acid coverage).
A-1 A-2 A-3 B-1 B-2 B-3 C-1 C-2 C-3 D-1 D-2 D-3
S1 30 58 26 35 69 55 36 49 61 23 41 58
S2 6 33 28 20 39 31 ND 14 16 ND 5 19
S3 ND 28 18 18 39 49 ND 12 22 ND 18 20
S4 20 53 13 41 57 42 ND 28 ND ND 28 ND
S5 ND ND 8 ND ND 8 ND ND ND ND ND 8
-ND: Not Detected
-Pertussis toxin Subunits (S1–S5)
-Sources: Pertussis toxins (A and B) and Pertussis toxoids (C and D)
-Instruments: 1–MALDI-TOF MS (4800 Proteomics Analyzer), 2–ESI-MS
(LTQ-Orbitrap), and 3–ESI-MS (Q-Tof)
proved to be more fruitful in terms of yielding a higher-
sequence coverage and an increase in peptide detection.
Speciﬁcally, S1 gave a higher-percent coverage by LC-
MS/MS instruments resulting in a 1.7-fold higher-overall
averageascomparedtotheMALDI-TOFmass-spectrometric
approach.
Tryptic digestions supplemented with RG resulted in an
increaseinsequencecoverageinallsamplesanddiﬀerentially
within the subunits (Table 3). RG had a greater eﬀect on the
Ptxd giving rise to the greatest increase in sequence coverage.
Ptxd D (2.2) resulted in a slightly greater overall fold change
as compared to Ptxd C (1.6), in the presence of RG, while
fold changes between all subunits were lower in both Ptx A
(0.5) and Ptx B (1.3). Collectively for both Ptx and Ptxd, S1,
S3, and S5 had marked gains in the presence of RG with a
nearly 1.5, 2.5, and 10-fold increase, respectively.
AsthesequencecoverageincreasedinthepresenceofRG,
the number of peptides detected by LC-MS/MS increased
as well and to a lesser extent in MALDI-TOF (data not
shown). Since the LC-MS/MS LTQ Orbitrap instrument
gave the optimum sequence coverage (in particular for the
toxins) in the presence of RG, a comparative assessment
of peptide detection for Ptx subunits among all sources
was compiled (Table 4). Table 4 reveals common and uniqueJournal of Biomedicine and Biotechnology 5
Table 2: Mass spectrometry-detected peptides found among all pertussis toxins and toxoids.
Peptides Detected Toxin A Toxin B Toxoid C Toxoid D
S1 DDPPATVYR (35–43) X X X
SCQVGSSNSAFVSTSSSR (74–91) X X
YTEVYLEHR(93–101) XX X X
MQEAVEAER(102–110) XX X X
GTGHFIGYIYEVR (114–126) XX X X
ADNNFYGAASSYFEYVDTYGDNAGR (127–151) X X X X
ILAGALATYQSEYLAHR(152–168) XX X X
IPPENIR(170–176) XX X X
VYHNGITGETTTTEYSNAR (181–199) X X X
YVSQQTRANPNYTSR (200–215) X
ANPNPYTSR (207–215) X
SVASIVGTLVR (217–227) XX X X
QAESSEAMAAWSER(239–252) XX X X
S2 ALTVAELR (56–63) X X X
GSGDLQEYLR (64–73) XX X X
GWSIFALYDGTYLGGEYGGVIK (78–99) X X
DGTPGGAFDLK (100–110) XX X X
NTGQPATDHYYSNVTATR (120–137) X X X
LCAVFVR (146–152) X
SGQPVIGACTSPYDGK (153–168) X X X
MLYLIYVAGISVR (179–191) X
S3 ALFTQQGGAYGR (39–50) XX X X
ALTVAELR (57–64) X X X
GNAELQTYLR (65–74) X X X
QITPGWSIYGLYDGTYLGQAYGGIIK (75–100) X X X
DAPPGAGFIYR(101–111) XX X X
ETFCITTIYK(112–121) XX X X
TGQPAADHYYSK (122–133) X X X
LLASTNSR (139–146) X
LCAVFVR (147–153) X
DGQSVIGACASPYEGR (154–169) X
DMYDALR (172–178) X
LLYMIYMSGLAVR (180–192) X X
S4 DVPYVLVK (43–50) X
TNMVVTSVAMKPYEVTPTR (51–69) XX X X
MLVCGIAAK (70–78) X
LGAAASSPDAHVPFCFGK (79–96) X X
RPGSSPMEVMLR (100–111) XX X X
QLTFEGKPALELIR (128–141) X X X
S5 NFTVQELALK (43–52) X X X
-Detected peptide present in source (X-box); Detected peptide absent in source (white box)
-Common peptide (detected among all sources)
-Instruments: MALDI-TOF, LTQ-Orbitrap & Q-Tof Premier (−) Rapigest
peptides that were detected among Ptx and Ptxd sources
analyzed. More importantly, an in-depth visual scan analysis
of MS/MS spectra of the common peptides revealed similar
fragmentation proﬁles (based on y- and b-ion distribution
and relative intensity of fragment ions), suggestive of Ptx
subunit sequence homogeneity as illustrated in Figure 1.
In addition to the determination of sequence homo-
geneity among sources, the relative amounts of protein as
measured by relative abundance (fmol) of subunits from
Ptx and Ptxd was preliminarily explored (Table 5). An LC-
MS/MS approach was used, in which the Q-Tof MSE data
were employed for this assessment in which diﬀerential6 Journal of Biomedicine and Biotechnology
Table 3: Comparative pertussis toxin and toxoid subunit sequence
analysis (−/+ rapigest treatment).
Subunit Source
− RG
(% AA
coverage)
#
peptides
detected
+R G
(% AA
coverage)
#p e p t i d e s
detected
S1
Toxin A 58 10 57 10
Toxin B 69 12 74 12
Toxoid C 49 8 66 10
Toxoid D 41 7 70 11
S2
Toxin A 33 4 31 4
Toxin B 39 4 45 7
Toxoid C 14 2 14 2
Toxoid D 5 1 14 2
S3
Toxin A 28 5 49 8
Toxin B 39 6 60 9
Toxoid C 12 2 38 6
Toxoid D 18 2 33 5
S4
Toxin A 53 4 28 2
Toxin B 57 4 41 3
Toxoid C 28 2 28 2
Toxoid D 28 2 50 4
S5
Toxin A — — 10 1
Toxin B — — 18 2
Toxoid C — — 10 1
Toxoid D — — 10 1
-Approach: Electrospray Ionization Mass Spectrometry-Instrument: LTQ-
Orbitrap only-RG (Rapigest)
abundance was revealed among sources and the subunits.
The absolute abundance of Ptx B was 7.2-fold higher among
allsubunitscomparedtoPtxA.PtxBS4gavethehighestfold
change at nearly 19 in comparison to Ptx A. With respect
to Ptxd, the abundance was nearly the same for all of the
subunits, with Ptxd D S1 revealing the highest fold change
(1.5) versus Ptxd C.
4. Discussion
We initiated a study using mass spectrometry to determine
if AA sequence diﬀerences exist between Ptx and Ptxd when
examined from diﬀerent sources. Using proteins (i.e., Ptx)
from strains that may not share the exact same AA sequence
or that have undergone diﬀerent inactivation treatments
could result in diﬀerences in immune eﬀectiveness. Protein
sequence variation between strains may be small (i.e., single
AA addition, deletion, or substitution) or potentially more
extensive with the addition or deletion of immunogenically
relevant motifs or domain structures. As a result, protein
sequence variance could lead to subtle structural, confor-
mational, and/or functional diﬀerences that can be detected
only through the use of sensitive technologies.
Previous MS investigations have been used for iden-
tiﬁcation, diﬀerentiation, and characterization of protein
complexes. For example, Nandakumar et al. [22] utilized MS
techniques for identiﬁcation of bacterial proteins. Protein
mixtures were subject to tryptic in-solution digestion and
analyzed by reverse phase nano LC-MS/MS followed by
database analysis. Other investigators have used MALDI-
TOF MS/MS for the analysis of peptides generated from the
enzymatic cleavage of Clostridium botulinum C3 coenzyme
[23]. Also, Yoder and colleagues analyzed tryptic digests of
Vaccinia virus using MALDI-TOF, as well as a quadrupole
iontrapmassspectrometerandaquadrupoleTOFtoidentify
proteins associated with infection [24]. Additionally, nano-
LC-MS/MS was used to identify AA variability between two-
bovine surfactant proteins [25]. In our study, an analytical
and proteomic evaluation was conducted to assess any
composition (i.e., AA sequence of the protein components)
and formulation (i.e., how much of a speciﬁc component)
disparities among Ptx and Ptxd.
Based on AA coverages and peptide detection alone, the
two Ptxs and two Ptxds appear to have similar sequences,
an indication that they were derived from the same origin,
although diﬀerent puriﬁcation schemes and inactivation
methods most likely were employed. The fact that the Ptx
and Ptxd sources shared similar tryptic digest patterns, in
terms of the peptides being generated and detected as well
as spectrum proﬁles, suggests homogeneity. The presence of
RG improved protein digestion resulting in higher-percent
coverages generally across source as well as Ptx subunits.
In addition, RG treatment appeared to have exposed the
smallest-sized S5, resulting in an increase in coverage for
this subunit. In doing so, additional peptides were detected
that once again were shown to be similar among Ptx and
Ptxd sources based on y- and b-ion distribution and relative
intensities of the fragmented peptides. Moreover, studies by
Sekura et al. [26] revealed, by amino acid analysis, that Ptx
puriﬁed from Bp strain 165 was indistinguishable from Ptx
prepared from the well-characterized Bp Tahoma strain. In
addition, Tummala et al. conﬁrmed Ptx sequence homo-
geneity among their Bp culture supernatant puriﬁed Ptx as
compared with previously reported sequence information
[19]. These data are conﬁrmatory and strengthen the MS
results in this study for Ptx sequence homogeneity. However,
although the data suggest protein sequence homogeneity,
if the sequence is indeed diﬀerent but not present in
the database then, upon searching, the generated peptides
would not be detected resulting in a lower peptide map
coverage.
Ptx is a major virulence factor and in its natural state has
physiological inhibitory eﬀects [11]. The subunits are highly
immunoreactive, including the dominant S1, making it an
ideal component for vaccines. To reduce the cellular lethality
induced by Ptx, the Ptx is inactivated or detoxiﬁed in its ﬁnal
vaccine form. Inactivation occurs by chemical modiﬁcation
(i.e., formaldehyde or glutaraldehyde) via the formation of
covalentcrosslinkingsontargetedAA(usuallylysines).Inter-
estingly in Ptxd samples, the oligomeric containing subunits
percent AA coverage was lower. The S2–S5 subunits, rich in
lysine are the subunits that are known to be heavily modiﬁed
due to the chemicalaction exhibited by formaldehydeand/or
glutaraldehyde [13, 27, 28]. As a result of modiﬁcation, these
peptides and subsequent MS-MS proﬁles would thus not beJournal of Biomedicine and Biotechnology 7
Table 4: Peptide detection among pertussis toxin and toxoid subunits (−/+ rapigest treatment).
− RG + RG
S1
GTGHFIGYIYEVR (114–126)
GTGHFIGYIYEVR (114–126) YTEVYLEHR (93–101)
YTEVYLEHR (93–101) MQEAVEAER (102–110)
MQEAVEAER (102–110) IPPENIR (170–176)
IPPENIR (170–176) VYHNGITGETTTTEYSNAR(181–199)
ILAGALATYQSEYLAHR(152–168)
MAPVIGACMAR(228–238)
S2 GSGDLQEYLR (64–73) GSGDLQEYLR (64–73)
NTGQPATDHYYSNVTATR (120–137)
S3 ALFTQQGGAYGR (39–50)
ALFTQQGGAYGR (39–50)
QITPGWSIYGLYDGTYLGQAYGGIIK (75–100)
GNAELQTYLR (65–74)
DAPPGAGFIYR (101–111)
S4 TNMVVTSVAMKPYEVTPTR (51–69) TNMVVTSVAMKPYEVTPTR (51–69)
RPGSSPMEVMLR (100–111)
S5 NFTVQELALK (43–52)
-Peptides detected in+RG (rapigest) (in bold) -Approach: Electrospray Ionization Mass Spectrometry-Instrument: LTQ-Orbitrap only
Table 5: Comparative pertussis toxin and toxoid subunit quantita-
tive analysis.
Source S1 S2 S3 S4 S5 Total (all subunits)
Toxin A 0.38 0.19 0.13 0.02 0.09 0.81
Toxin B 1.48 2.04 1.35 0.37 0.57 5.81
Toxoid C 1.88 0.34 0.32 ND ND 2.54
Toxoid D 2.91 0.40 0.21 ND 0.06 3.54
-Measured as relative abundance (fmol/μL)
-ND: not detected
-Approach: Electrospray Ionization Mass Spectrometry
-Instrument: Q-Tof Premier only
detected using traditional selected database searching tools
resulting in lower AA coverages.
Although formaldehyde, for instance, is an ideal reagent
for chemical crosslinking, it also immobilizes the antigen
(i.e., Ptx) and alters its conformation preventing a natural
interaction between the antibody and antigen. In other
words, formaldehyde reduces the accessibility of antibodies
to their epitopes by creating steric hindrance or by altering
the epitope site itself. In Ptxd samples, inactivation by
formaldehyde appears to have a severe impact on peptide
detection, due to crosslinking of lysine on the Ptx subunits
[13, 27–29]. These subunits are most likely masked pre-
venting trypsin, whose natural recognition sites are lysine
and arginine, to eﬀectively cleave the protein resulting in
a lower AA coverage. On a cellular level, it is sensible for
these subunits to be inactivated heavily, since in vivo, they
make up the oligomeric complex that adheres to the human
host cells which upon binding to the appropriate receptor
initiates Ptx function. Blocking these cellular activities, in
essence, inhibits or diminishes further downstream enzy-
matic activity by S1, which would allow for progression of
normal immune responses by the host towards Bp. Besides,
S1 has consistently had higher AA coverage reporting among
all sources, which could be explained by the fact that S1
lacks lysines. Although S1 is deﬁcient in lysine, free cellular
lysine in the presence of formaldehyde would still create
crosslinking bridges that lead to the detoxiﬁcation [28, 29]
but to a lesser extent compared to S2–S5. As a result
of minimal chemical bombardment and thus potentially
incomplete inactivation by formaldehyde on the toxic S1
component, residual toxicity may remain, withvarying levels
among Ptxd sources, could lead and be an explanative factor
for diﬀerential immunity, albeit speculative.
5. Conclusions
In conclusion, this study incorporated multiple mass-
spectrometric approaches to identify protein sequence sim-
ilarities among Ptx and Ptxd sources, based on AA cover-
age proﬁles, peptide detection, and fragmentation proﬁles.
Lower-percent coverage among Ptxd oligomeric subunits
as compared to S1 could be explained most likely due to
chemical modiﬁcations. As a result of these modiﬁcations,
inactivation of Ptx subunits, as evident by failed detection
of peptides, could lead to diminished immuno-cellular
interactions between human-generated antibodies against
chemically modiﬁed Bp antigens. In addition to the protein
components, changes in the formulation, including the
concentration,ratioandabundanceofthePtxsubunitscould
translate into diﬀerences with respect to immune responses
and vaccine eﬃcacy. Moreover, information from this MS
study could prove useful in improving immunological tests
that use Ptx as an examining factor for vaccine evaluation
and even pertussis diagnosis.
Future studies such as de novo sequencing or protein
sequence tag analysis may be considered to validate and8 Journal of Biomedicine and Biotechnology
strengthen the current ﬁnding that the protein sequences
among all the sources are indeed homogeneous. In addition,
incorporation of other enzymes in the presence of RG to
expand the AA coverage and peptide detection may also
be performed. Also, a comparative quantitative MS analysis
assessing the functionality of Ptx and Ptxd sources may be
able to determine the eﬀect, if any, that Ptx inactivation, Ptx
function, and potential residual toxicity play on vaccine eﬃ-
cacysuchasimmuneresponses.Lastly,invivoanimalstudies
may be conducted to examine the correlation between Ptx
protein sequence homogeneity and immunoreactivity.
Disclaimer
The references in this paper to any speciﬁc commercial
products, process, service, manufacturer, or company do
not constitute an endorsement or a recommendation by the
U.S. Government or the Centers for Disease Control and
Prevention. The ﬁndings and conclusions in this paper are
those of the authors and do not necessarily represent the
views of CDC.
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